A Novel Molecular Grading Model: Combination of Ki67 and VEGF in Predicting Tumor Recurrence and Progression in Non-invasive Urothelial Bladder Cancer |
Chen, Jun-Xing
(Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University)
Deng, Nan (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) Chen, Xu (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) Chen, Ling-Wu (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) Qiu, Shao-Peng (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) Li, Xiao-Fei (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) Li, Jia-Ping (Department of Interventional Oncology, the First Affiliated Hospital of Sun Yat-Sen University) |
1 | Al-Abbasi DS, Al-Janabi AA, Al-Toriahi KM, et al (2009). Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study. Appl Immunohistochem Mol Morphol, 17, 307-11. DOI |
2 | Bryan RT, Zeegers MP, James ND, et al (2010). Biomarkers in bladder cancer. BJU Int, 105, 608-13. DOI |
3 | Chade DC, Shariat SF, Godoy G, et al (2009). Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Mens Health, 6, 368-82. DOI |
4 | Cheng L, Neumann RM, Weaver AL, et al (1999). Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol, 17, 3182-7. DOI |
5 | El-Chennawi FA, Auf FA, Metwally SS, et al (2009). Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer. World J Gastrointest Oncol, 1, 62-8. DOI |
6 | Evans CP, Debruyne F, Payne H, et al (2007). Bladder cancer: Management and future directions. Eur Urol Suppl, 6, 365-73. DOI |
7 | Fauconnet S, Bernardini S, Lascombe I, et al (2009). Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep, 21, 1495-504. |
8 | Gonul II, Akyurek N, Dursun A, et al (2008). Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract, 204, 707-17. DOI |
9 | Habuchi T, Marberger M, Droller MJ, et al (2005). Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 66, 64-74. DOI ScienceOn |
10 | Hilmy M, Campbell R, Bartlett JM, et al (2006). The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX- 2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer, 95, 1234-8. DOI ScienceOn |
11 | Kilicarslan AB, Ogus M, Arici C, et al (2003). Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. Apmis, 111, 439-43. DOI ScienceOn |
12 | Klein M, Vignaud JM, Hennequin V, et al (2001). Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab, 86, 656-8. DOI ScienceOn |
13 | Lebret T, Becette V, Herve JM, et al (2000). Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol, 37, 654-9. DOI ScienceOn |
14 | Li R, Heydon K, Hammond ME, et al (2004). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res, 10, 4118-24. DOI |
15 | Margulis V, Lotan Y, Karakiewicz PI, et al (2009), Multiinstitutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst, 101, 114-9. DOI |
16 | Margulis V, Shariat SF, Ashfaq R, et al (2006). Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 12, 7369-73. DOI |
17 | Santos L, Amaro T, Costa C, et al (2003). Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer, 105, 267-72. DOI |
18 | M Burger SDAH (2007). Mcm2 predicts recurrence hazard in stage TaT1 bladder cancer more accurately than CK20 Ki67 and histological grade. Br J Cancer, 96, 1711-5. DOI |
19 | Oka N, Yamamoto Y, Takahashi M, et al (2005). Expression of angiopoietin-1 and-2, and its clinical significance in human bladder cancer. Bju Int, 95, 660-3. DOI |
20 | Sakamoto S, Ryan AJ, Kyprianou N (2008). Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem, 103, 691-708. DOI |
21 | Shirotake S, Miyajima A, Kosaka T, et al (2011). Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology, 77, e19-25. DOI |
22 | van der Loos CM, Meijer-Jorna LB, Broekmans ME, et al (2009). Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels. J Histochem Cytochem, 58, 109-18. |
23 | van Rhijn BW, Vis AN, van der Kwast TH, et al (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol, 21, 1912-21. DOI |
24 | van Rhijn BW, Zuiverloon TC, Vis AN, et al (2010). Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol, 58, 433-41. DOI |
25 | Yurakh AO, Ramos D, Calabuig-Farinas S, et al (2006). Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol, 50, 506-15; discussion 515. DOI |
26 | Viale G, Regan MM, Mastropasqua MG, et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12. DOI |
27 | Vidal O, Soriano-Izquierdo A, Pera M, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14. DOI |
28 | Wolman SR, Goldman B, Slovak ML, et al (2007). Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet, 176, 22-7. DOI |